euportal twitter euportal facebook

Commission and EIB provide loan for CureVac for vaccine development

COVID -19

6.7.2020 – The European Investment Bank (EIB) and CureVac, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimised mRNA, entered into a €75 million loan agreement to support the Company’s ongoing development of vaccines against infectious diseases, including its vaccine candidate CVnCoV aimed at preventing SARS-CoV-2 infections. In addition, the [...]

Read more